New Phase 3 data for envudeucitinib announced at #FallClinical2026 showed rapid, durable reductions in PsO disease burden across scalp, itch, and quality-of-life measures, building on the high‑threshold skin clearance observed in ONWARD. NDA submission on track for 4Q 2026. Learn more: bit.ly/4rVOwPu

We’re in Las Vegas for #FallClinical2026! Sharing new Phase 3 data on envudeucitinib, our investigational next‑gen TYK2i for plaque #psoriasis. Want to learn more? Explore our posters in the exhibit hall and stop by our tabletop in the Cristal Ballroom to meet the team.

UPDATED: Alumis is in Vienna for #EADV2026. Stop by Booth X2004 to meet the team and learn more about envudeucitinib, our investigational next‑gen TYK2i for plaque #psoriasis. Explore our #EADVCongress e‑posters here: bit.ly/4xXDTNN

Alumis is in Vienna for #EADV2026. Stop by Booth 5712 to meet the team and learn more about envudeucitinib, our investigational next‑gen TYK2i for plaque #psoriasis. Explore our #EADVCongress e‑posters here: bit.ly/4xXDTNN

Members of our executive committee will be on the road in September, with investor meetings and conference participation in Boston and New York. Full schedule: bit.ly/4gQRSOY

Today we announced our Q2 2026 financial results and upcoming milestones for envudeucitinib - potentially pivotal Phase 2b topline results in SLE expected in Q3 and an NDA submission for moderate-to-severe plaque psoriasis planned for Q4. bit.ly/4x1STKM

Today we announced our Q2 2026 financial results and upcoming milestones for envudeucitinib - potentially pivotal Phase 2b topline results in SLE expected in Q3 and an NDA submission for moderate-to-severe plaque psoriasis planned for Q4. bit.ly/4x1STKM

ONWARD3 LTE data for envudeucitinib are in: 54% achieved PASI 100—the highest reported among oral PsO therapies, durable skin clearance, and long‑term safety data remained consistent with ONWARD 1/2. bit.ly/3S50Srg

We recently spent time with Dr. Ehst to hear about the burden of psoriasis. In this video, he shares why it’s more than a skin condition and why its whole‑body impact matters.

We’re at the Congress of Clinical Dermatology and PANP360 this week. Visit our exhibit table to learn more about envudeucitinib, our investigational TYK2i for plaque psoriasis.

Today we announced our Q1 2026 financial results, along with recent achievements and key upcoming milestones. Learn more: bit.ly/4noy48a

Catch our poster on 5/14 at #SIDChicago26, where we’ll present biomarker data on envudeucitinib, an investigational oral treatment for PsO. Learn more: bit.ly/4en0JIq

New manuscript in Dermatology and Therapy explores how envudeucitinib’s TYK2 MOA and P2 data make it a promising next-gen oral therapeutic candidate for PsO. bit.ly/4duNDsf

Dr. Ehst explains how TYK2 inhibitors focus on the immune cells causing psoriasis, easing skin inflammation without affecting the rest of the immune system — and why that matters.

Late-breaker P3 data of our investigational TYK2i at #AAD2026 reinforced its potential as a leading oral therapy for psoriasis. Investor webcast 3/29 at 5pm MDT. bit.ly/EnvuAAD

Today we reported year-end 2025 financial results and a summary of recent achievements and upcoming milestones for envudeucitinib in plaque psoriasis and lupus: bit.ly/4bzoTwp

Envudeucitinib Phase 3 results were accepted for a late‑breaking oral at #AAD2026 on March 28. Investor webcast to follow March 29 at 5pm MDT / 7pm EDT. bit.ly/4rGhMZ3

Hear CEO Martin Babler discuss how Alumis leverages its genomic and genetic insights to design targeted medicines for immune‑mediated diseases. #AutoimmuneAwarenessMonth

Alumis CEO will join a fireside chat at the Leerink Partners Global Healthcare Conference on 3/9. Save the date and watch the live webcast or replay: lnkd.in/eFWyJx-J